Publication & Citation Trends
Publications
0 total
95P: Adagrasib (ADA) plus cetuximab (CETUX) in patients (pts) with advanced KRASG12C-mutated non-small cell lung cancer (NSCLC) from KRYSTAL-1
Cited by 1
Semantic Scholar
EP08.02-111 RMC-4630, a SHP2 Inhibitor, in Combination with Sotorasib for Advanced KRASG12C NSCLC After Failure of Prior Standard Therapies: A Phase 2 Trial OA
Cited by 7
Semantic Scholar
76TiP RMC-4630 and sotorasib for advanced KRASG12C NSCLC after failure of prior standard therapies: A phase II trial OA
Cited by 1
Semantic Scholar
The association between immune-related adverse events and efficacy outcomes with consolidation pembrolizumab after chemoradiation in patients with stage III NSCLC: an analysis from HCRN LUN 14-179.
Cited by 0
Semantic Scholar
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179 OA
Cited by 123
Semantic Scholar
P1.18-05 ChemoXRT W/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy OA
Cited by 2
Semantic Scholar
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)
Cited by 42
Semantic Scholar
Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.
Cited by 53
Semantic Scholar
Research Topics
Colorectal Cancer Treatments and Studies
(8)
Cancer Immunotherapy and Biomarkers
(7)
Neuroendocrine Tumor Research Advances
(7)
Lung Cancer Treatments and Mutations
(5)
Cancer Genomics and Diagnostics
(5)
Affiliations
Creighton University
Aurora Health Care
University of Iowa
Atrium Health Wake Forest Baptist
Indiana University Health